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Abstract
The development of melanocytes is regulated by the tyrosine kinase receptor c-KIT and the basic-helix-loop-helix-leucine
zipper transcription factor Mitf. These essential melanocyte survival regulators are also well known oncogenic factors in
malignant melanoma. Despite their importance, not much is known about the regulatory mechanisms and signaling
pathways involved. In this study, we therefore sought to identify the signaling pathways and mechanisms involved in c-KIT
mediated regulation of Mitf. We report that c-KIT stimulation leads to the activation of Mitf specifically through the c-KIT
phosphorylation sites Y721 (PI3 kinase binding site), Y568 and Y570 (Src binding site). Our study not only confirms the
involvement of Ras-Erk signaling pathway in the activation of Mitf, but also establishes that Src kinase binding to Y568 and
Y570 of c-KIT is required. Using specific inhibitors we observe and verify that c-KIT induced activation of Mitf is dependent
on PI3-, Akt-, Src-, p38- or Mek kinases. Moreover, the proliferative effect of c-KIT is dependent on Mitf in HEK293T cells. In
contrast, c-KIT Y568F and Y721F mutants are less effective in driving cell proliferation, compared to wild type c-KIT. Our
results reveal novel mechanisms by which c-KIT signaling regulates Mitf, with implications for understanding both
melanocyte development and melanoma.
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Introduction
Cell signaling plays an important role in the fine tuning of
cellular function and behavior. Signaling cascades generated by
the cell surface tyrosine kinase receptor c-KIT through the binding
of its ligand stem cell factor (SCF) are involved in the regulation
of many cell types including melanocytes [1], mast cells [2,3],
germ cells [4] and interstitial cells of Cajal [5]. Loss-of-function
mutations of the receptor or its ligand lead to abnormalities in
pigmentation [6–8], hematopoiesis [9,10], gametogenesis [11,12]
and gut motility [13]. The binding of SCF to c-KIT leads to
dimerization and auto-phosphorylation of tyrosine residues located
in the intracellular part of the receptor. Phosphorylation of
tyrosine residues enables c-KIT to recruit and bind to downstream
signaling proteins for subsequent activation of signal transduction
pathways. It is well characterized that the c-KIT phosphorylation
sites Y568 and Y570 can act as docking and activation sites for Src
family kinases. The transduction signal relayed from c-KIT to Src
kinases triggers the activation of the Ras-Erk pathway, involving
the pro-survival and anti-apoptotic Ras-Raf-Mek-Erk cascade
[14,15]. The activation of Src kinase also regulates the stress-
activated protein kinase p38 [16]. On the other hand, the
phosphatidylinositide 3 kinase (PI3 kinase) survival pathway is
switched on by phosphorylation of c-KIT at Y721. The activation
can either be set in motion by the direct binding of the p85 subunit
of PI3 kinase to Y721 or by binding of PI3 kinase to the scaffolding
protein Grb2 associated binding protein (Gab2). Grb2 that is
bound to phosphorylated Y703 and Y936 in c-KIT forms a bridge
to Gab2 [17–19]. Phosphorylation of Gab2 by Src creates binding
sites for PI3 kinase on Gab2. Since c-KIT is a pivotal player in
hematopoiesis, its signaling has been well characterized in
hematopoietic cells. Even though the importance of c-KIT in
melanogenesis is recognized and a loss-of-function mutation of the
receptor, or its downstream targets, can lead to developmental
pigmentary diseases like piebaldism and Waardenburgs syndrome,
the signaling cascades of c-KIT in melanocytes are not fully
elucidated [20,21].
Melanocytes are derived from the neural crest during
embryogenesis. In order for these cells to fully differentiate into
functional pigment producing melanocytes, these cells first have to
migrate and colonize target tissues, including the skin and hair
follicle. The program that enables such behavior is orchestrated by
the c-KIT tyrosine kinase receptor and its target, the melanocyte
master regulator Microphthalmia associated transcription factor
(Mitf) [22]. Consequently, loss-of-function mutation of Mitf give
rise to phenotypic defects in mice similar to that found in c-KIT
and SCF mutant mice in that coat color is lacking due to absence
of melanocytes and mutations in all three genes also affect mast
cells [23,24]. There are differences between Mitf mutations on the
one hand and c-KIT/SCF mutations on the other hand in that Mitf
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c-KIT and SCF have severe hematopoietic deficiencies which Mitf
mutations do not exhibit, at least not to the same degree.
Mitf is a basic helix-loop-helix-leucine-zipper transcription factor
that isnot onlyessentialformelanogenesisandmelanocytefunction,
butisalsoinvolvedinboneand mastcelldevelopment[25–28].Mitf
regulates a wide range of genes important for melanocyte and
melanoma proliferation, survival, differentiation, apoptosis and cell
cycle arrest (for review see [29]). The expression of the survival
factor CDK2 is maintained by Mitf in melanocytes and melanoma
and the BCL2 gene was found to be transcribed and upregulated by
Mitf under SCF stimulation [30,31]. In addition to cell survival,
Mitf regulates CDKN1A and CDKN2A expression to inhibit cell
growth and initiate differentiation [32,33].
To date, two mechanisms are known by which c-KIT regulates
the activity of Mitf. First, c-KIT phosphorylation activates the Ras-
Erk pathway where Erk2 directly phosphorylates S73 of Mitf. As a
result, the transactivation activity of Mitf is increased and the half-
life of the protein is decreased as a consequence of ubiquitin-
dependent degradation [34,35]. Second, Erk activation leads to
activation of the serine/threonine kinase p90 Rsk-1 that phosphor-
ylates Mitf at S409. Un-phosphorylated mutants at S73 and S409 of
Mitf render the transcription factor more stable and transcription-
ally less active [34,36]. At this point, however, it is not clear if S73
and S409 are the only phospho-acceptor sites in Mitf and, in fact,
several pieces of evidence suggest that they are not. First, the Mitf
protein has been shown to be phosphorylated on a number of serine
residues, in addition to S73, and S409. These include S298 and
S307 (reviewed in [29]). Second, genetic analysis of the role of
signaling to Mitf during normal melanocyte development using
knock-in and BAC transgene rescue strategies indicate that the S73
andS409donotplayaroleduringnormalmelanocytedevelopment
in mice [37,38]. Clearly, the signaling to Mitf needs to be further
characterized, both with respect to actual phosphoacceptor sites,
and with respect to the signaling mechanisms involved to be able to
understand the precise mechanism of regulation of Mitf activity.
In this report we have used a series of c-KIT mutants and
pharmacological inhibitors to identify the signaling pathways
radiating from c-KIT to Mitf in human embryonic kidney (HEK)
293T cells and in Melan-A melanocytes. We show that the
tyrosine-to- phenylalanine mutations Y568F, Y570F and Y721F in
c-KIT prevent activation of Mitf during SCF stimulation. In
contrast, the Y703F/Y936F c-KIT double mutant does not block
SCF-induced activation of Mitf. In addition, by using selective
inhibitors against Src, Mek 1 and 2, p38, PI3 kinase and Akt, we
show that the corresponding downstream signaling pathways are
involved in the activation of Mitf. Finally, our transfection model
revealed that the different c-KIT mutants together with wild type
(wt) Mitf yielded a lower degree of SCF-induced proliferation
compared to wild type c-KIT expressing HEK293T cells.
Materials and Methods
Cell culture
HEK293T cells (Thermo Scientific Open Biosystems) were
cultured in Dulbecco’s modified Eagle’s medium and supplemented
with 10% fetal bovine serum and 100 units/ml penicillin-
streptomycin. Mouse melanocyte Melan-A cells were cultured
according to recommended protocol (http://www.sgul.ac.uk/
depts/anatomy/pages/dcbm&m.htm). The Melan-A cell line was
a kind gift from Dr. Bennett.
BaF3 pro-B cells were maintained in RPMI-1640 medium
supplemented with 100 units/ml penicillin- streptomycin, 10%
heat inactivated fetal bovine serum and 10 ng/ml of IL-3.
Plasmids
QuikChange mutagenesis kit (Stratagene) was used to generate
tyrosine-to-phenylalanine substitution mutants of c-KIT contained
in pcDNA3 vector. P3XFLAG-CMV-14 (Sigma Aldrich) was used
as a vector backbone for the Mitf construct.
Transfection
Turbofect transfection reagent (Fermentas) was used for all the
experiments in this study according to manufacturer’s protocol.
Ligand stimulation and inhibitor treatment
SCF (ORF Genetics) was used for cell culture stimulation in a
final concentration of 100 ng/ml. In the inhibitor experiments,
10 mM of SU6656 (CalBiochem), U0126 (Promega), LY294002
(Sigma Aldrich) or 3 mM of Akt IV (CalBiochem) was pre-
incubated in cell culture medium for 30 minutes in 5% CO2,3 7 uC
prior to SCF stimulation.
Proliferation assay
HEK293T (4 million) cells were plated in 75 cm
2 cell culture
flasks (Nunc). One day after plating, cells were transfected with
both c-KIT and/or Mitf plasmids and incubated for 8 hours in a
cell culture incubator, after which the cells were washed 3 times
with PBS and cultured in serum starved medium. Cells that were
detached from culture flasks during the washing steps were
collected and resuspended. SCF was added the day after the initial
starvation procedure. Cells were trypsinized, resuspended in
culture medium, stained with trypan blue and analyzed with
Countess automated cell counter (Invitrogen) after 48 hours of
SCF stimulation.
Immunoblotting and immunoprecipitation
Cells were lysed for 15 minutes in cold lysis buffer containing
1% Triton X-100, 25 mM Tris, pH 7.5, 1 mM Na3VO4,1 %
Trasylol, 1 mM phenylmethylsulfonyl fluoride, 5 mM EDTA and
25mM beta-glycerophosphate. The lysates were centrifuged at
17,000 X g for 20 minutes at 4uC. The FLAG-tagged Mitf protein
was immunoprecipitated with monoclonal anti-FLAG M2 anti-
body (Sigma Aldrich). Human c-KIT was immunoprecipitated
with the KitC1 antibody [39]. Mouse c-KIT was immunoprecip-
itated with the M-14 anti-c-KIT antibody (Santa Cruz, CA). After
antibody addition, the cell lysate was incubated with rotation at
4uC for 1.5 hours. The immunoprecipitates were collected on
protein G-Sepharose beads (GE Healthcare), washed three times
in lysis buffer supplemented with above mentioned inhibitors.
Protein elution was carried out by boiling 4 minutes in sample
buffer (50 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol,
200 mM dithiothreitol, 12.5 mM EDTA and 0.02% bromophenol
blue). After sample separation in SDS-PAGE with 8% continuous
gel, proteins were electrotransferred to Immobilon P (Millipore)
membranes using a semi-dry blotting system (BioRad). The
membranes were blocked in 0.2% Tween 20 in PBS for 1 hour
at room temperature. Primary and secondary horseradish peroxidase-
conjugated antibody incubation was performed at room tempera-
ture for 1 hour. Prior to incubation with the secondary antibody the
membranes were washed extensively with 0.5% Tween 20 in PBS.
Finally, Immobilon Western chemiluminescent HRP substrate
(Millipore) was used for protein detection.
Mitf mobility shift quantitation
Mitf protein intensity was measured with ImageJ as outlined at
the NIH website: http://rsbweb.nih.gov/ij/docs/menus/analyze.
html. The intensity of the low molecular weight band was
KIT/Mitf Effects on Cell Proliferation
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According to this method a protein mobility shift seen as increased
intensity of the heavy molecular weight protein band, produces a
positive value. A resulting negative value indicates inactive state of
Mitf. Each bar in the mobility shift quantitation charts in this study
represents the average from three independent experiments. Error
bars are reported as standard error of the mean.
Statistical analysis
Eachdata set from Mitf mobility shift assays and cell proliferation
experiments represents the mean for three and nine separate
experiments, respectively. One way analysis of variance was used to
analyze significant differences in cell proliferation assay. Significant
results were further examined by a Newman- Keuls multiple
comparison test. A p-value of ,0.05 was considered significant. A
2-tail non parametric sign test was performed on Mitf mobility shift
assay data, where the criterion for significance was set as p,0.05.
Results
Mitf is activated upon c-KIT stimulation
Ligand-stimulation of c-KIT post transcriptionally modifies Mitf
through Erk-dependent phosphorylation of Mitf at S73 and S409.
Addition of these phospho-groups can easily be detected by
Western blotting where the modifications generate a mobility shift
of the Mitf protein [34,36]. Previous mobility shift studies were
mostly performed with endogenous c-KIT and Mitf in melano-
cytes and melanoma cells. Because of this we needed to verify
that our transfection model with HEK293T cells and mouse
melanocyte Melan-A cells would produce equivalent results. Mitf
in unstimulated state resolves as one heavy (upper) and one light
(lower) molecular weight band with a higher intensity of the lower
band. We transfected HEK293T cells with both c-KIT and Mitf
whereas Melan- A cells were only transfected with Mitf. After
15 minutes of SCF stimulation in both HEK293T and Melan-A
cells the band intensity of Mitf shifted resulting in increased
intensity of the heavy band. (Fig. 1A & B). The intensity shift of
Mitf was partly reversed back to basal state after 30 minutes of
SCF stimulation. We further tested Mitf protein shift in HEK293T
cells by generating serine to alanine substitution mutation of Mitf
at position 73 and/or 409 and then transfecting these mutants or
wt Mitf together with c-KIT. As expected, mobility shift of wt Mitf
was detected after 15 minutes of SCF stimulation (Fig. 2).
However, single substitution mutation of S73 or S409 and double
mutation of S70/409A completely removed the upper band of the
protein regardless of SCF stimulation. These results illustrate that
SCF induced mobility shift of Mitf is dependent on S73 and S409.
Collectively, our data from these cell lines are in agreement with
previous reports, suggesting that our transfection model can be
used for further signaling studies.
C-KIT phosphorylation sites Y568, Y570 & Y721, but not
Y703/963, are required for Mitf activation
SCF binding to c-KIT causes auto-phosphorylation of various
tyrosine residues in the intracellular domain of c-KIT. To pinpoint
the involvement of the specific phospho-tyrosine residues involved
Figure 1. C-KIT activation induces a mobility shift of Mitf. (A) HEK293T cells transfected with c-KIT and Mitf and (B) Melan-A cells transfected
with only Mitf displays mobility shift, where the upper band becomes more intense than the lower band, after 5–15 min of SCF (100 ng/ml)
stimulation.
doi:10.1371/journal.pone.0024064.g001
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to-phenylalanine c-KIT mutants. In this experiment we used
the HEK293T and mouse melanocyte Melan-A cell lines and
transfected both c-KIT and Mitf into the cells. Because the Melan-
A cells have endogenous expression of both wt Mitf and wt c-KIT,
we needed to bypass the signals generated from wt mouse c-KIT
in order to avoid interference with the transfected human
c-KIT mutants. The activation of c-KIT can be detected by a
general anti-phosphotyrosine monoclonal antibody (4G10 from
Sigma Aldrich) after immunoprecipitation of the c-KIT protein. In
the Melan-A cells, endogenous mouse c-KIT was phosphorylated
after 5–15 min of mouse SCF (mSCF) stimulation (Fig. 3A).
Furthermore, after 30 min to 1 hour of stimulation the level of
endogenous c-KIT was decreased due to phosphorylation depen-
dent internalization of the receptor. However, by using human SCF
(hSCF) we were able to avoid the activation of the endogenous
mouse c-KIT protein altogether (Fig. 3B).
Phosphorylation of c-KIT sites Y568 and Y570 (with Y568
being the primary activation site) allows docking and activation of
Src family kinases leading to the activation of the Ras-Raf-Mek-
Erk signaling cascade [15,16]. The Erk signaling pathway as the
activator of Mitf is well characterized [34,36,40,41]. To determine
Figure 2. Mitf upper band is abolished by S73A, S409A and
S73/409A substitution mutations. Transfection with wt Mitf in
HEK293T cells shows a mobility shift after 15 minutes of SCF
stimulation. In contrast, the S73A, S409A and S73/409A mutations of
Mitf completely eliminate the heavy molecular weight band of Mitf,
independent of hSCF treatment.
doi:10.1371/journal.pone.0024064.g002
Figure 3. Human SCF (hSCF) does not activate mouse c-KIT. (A) Endogenous mouse c- kit immunoprecipitated from Melan-A cells stimulated
with mouse SCF (mSCF) was autophosphorylated. (B) However, the addition of hSCF to the Melan-A cells did not activate endogenous mouse c-KIT.
Immunoblotting with 4G10 antibody was used to detect general tyrosine phosphorylation to assess the c-KIT phosphorylation/ activation.
doi:10.1371/journal.pone.0024064.g003
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potentially Src kinase are involved in the activation of Mitf
we transfected c-KIT mutants Y568F and Y568/570F into both
HEK293T and Melan-A cells together with Mitf. When sti-
mulated with SCF these c-KIT mutants blocked the activation of
Mitf as determined by reduced mobility shift of the protein (Fig. 4).
Our results suggest that the c-KIT phosphorylation sites Y586 and
Y570 are involved in the signaling to Mitf and that Src might play
a role in this event.
The PI3 kinase survival pathway involving the serine/ threonine
kinase Akt has been shown to protect melanocytes from apoptosis
[42] and is also involved in the regulation of Mitf [43,44]. The
activation of the PI3 kinase pathway by c-KIT can be triggered
through two alternative pathways [17–19]: first, through direct
binding of p85 (subunit of PI3 kinase) to c-KIT phosphorylation
site Y721. Second, c-KIT phosphorylation residues Y703 and
Y936 can serve as binding sites for Grb2, allowing Grb2 to form a
complex with Gab2, to which p85 can bind and interact. As a
consequence of the interaction the PI3 kinase pathway is activated.
In our transfection model, SCF stimulation of c-KIT Y721F
mutant inhibited Mitf activation, indicating that phosphorylation
of c-KIT at Y721 is needed in the activation of Mitf and that the
PI3 kinase pathway might be involved (Fig. 4). However, despite
impeded Grb2 binding sites, the c-KIT mutant Y703/936F was
still able to cause a mobility shift of Mitf after the addition of SCF.
Further examination showed that neither the HEK293T cells nor
the Melan- A cells maintain an endogenous expression of Gab2
protein compared to the positive control pro-B BaF3 cells (Fig. 4C).
Because c-KIT utilizes both direct (Y721) and indirect (Y703/936)
binding of p85 to activate the PI3 kinase pathway, the lack of
Gab2 in our cell lines favored the direct pathway, thus, rendering
the Y703/936 c-KIT docking sites dispensable for the activation of
Mitf.
In all, these observations illustrate that the activation of Mitf by
c-KIT is dependent on functional direct docking sites for the PI3
kinase subunit p85 and Src kinase on c-KIT Y721 and Y568,
respectively. Also, the data show that c-KIT phosphorylation sites
Y703/936 are obsolete.
C-KIT activates Mitf through the signaling proteins Src,
Mek, PI3 kinase, Akt and p38
The role of Src kinase in the activation of Mitf has not been
investigated previously nor has the PI3 kinase-Akt pathway been
studied in the context of c-KIT- induced Mitf activation. To
investigate this, we treated cells with either Src family kinase
inhibitor (SU6656), Mek inhibitor (U0126), PI3 kinase inhibitor
(LY294002) or Akt inhibitor (Akt IV) for 30 minutes prior to SCF
stimulation. The addition of SCF to untreated samples caused a
mobility shift or activation of Mitf. However, pre-treatment with
SU6656, U0126, LY294002 or Akt IV inhibited the activation of
Mitf in all cases (Fig. 5). These observations suggest that Src
kinases, Mek, PI3 kinase and Akt are all involved in SCF-induced
Mitf phosphorylation.
The stress activated protein kinase p38 acts downstream of c-
KIT and is known to be involved in the activation of Mitf gene
expression in response to UV radiation [45]. In contrast, when
human melanocytes are exposed to UV-B, p38 increases the
expression of Mitf which in turn up-regulates the protein level of c-
KIT via unknown mechanisms [46]. To test whether p38 is
involved in SCF-induced Mitf activation, we employed the p38
inhibitor SU203580. Pre-treatment with SU203580 completely
blocked SCF-induced Mitf mobility shift (Fig. 5), indicating that
the signal from c-KIT to Mitf can also be mediated through p38.
Our results not only confirm that c-KIT activates Mitf through
the Ras-Erk pathway as previously reported [34,36], but show that
this mechanism is Src kinase-dependent. Our inhibitor studies also
demonstrate that upon SCF stimulation, c-KIT triggers the
activation of Mitf through the stress activated p38 kinase and
the survival PI3 kinase-Akt pathway.
C-KIT and Mitf mediated cell proliferation
Mitf activates transcription of a wide array of genes that regulate
both cell survival and cell death [30,41,47,48]. In melanocytes and
melanoma the survival gene BCL2 is transcribed as a consequence
of c-KIT- mediated Mitf activation [31]. To study the biological
function resulting from the c-KIT and Mitf interaction in the
HEK293T cell model we transfected this cell line with either wt c-
KIT or mutant form of c-KIT together with wt Mitf. Treatment of
serum-starved HEK293T cells with SCF for 48 hours in the
presence of wt c-KIT and wt Mitf, promoted enhanced cell growth
(Fig. 6). However, when the cells were transfected with the c-KIT
mutants Y568F or Y721F together with wt Mitf, SCF stimulation
yielded a significantly reduced level of cell growth compared to wt
c-KIT. In contrast, the Y703F/Y936F double mutant of c-KIT
that lacks functional Grb2 binding sites (that could bind to Gab2)
did not significantly produce lower cell proliferation rate com-
pared to wt c-KIT. This result can be explained by the fact that
the HEK293T cells do not maintain an endogenous level of Gab2
protein (Fig. 4C). The addition of SCF for 48 hours to c-KIT
Y568F, Y721F and Y703/936 mutants significantly (p,0.01,
p,0.01 and p,0.001, respectively) augmented cell growth
compared to respective 0 hour negative control. In addition,
control cells transfected with only c-KIT or Mitf did not produce
any proliferative effects upon SCF stimulation (Fig. 6).
Our results show that SCF-dependent cell proliferation is only
achieved in the HEK293T cells when wt c-KIT and wt Mitf are
present. Although, c-KIT mutants that lack functional Src and
p85 binding sites can mediate ligand-induced cell proliferation, the
response is severely impaired compared to the wild-type receptor.
Discussion
The mechanisms behind c-KIT activation are well studied.
When c-KIT is bound to its ligand, SCF, the receptor dimerizes,
leading to auto-activation of the cytoplasmic tyrosine kinase
domain [49]. Subsequent phosphorylation of additional tyrosine
residues in c-KIT enables downstream signaling proteins to bind
to the receptor. These events result in the activation of many
different signaling pathways. In contrast, the c-KIT signaling
mechanisms involved in the activation of Mitf in melanocytes are
not fully understood. To date, the Ras-Erk pathway is the only
known signaling cascade that has been shown to participate in the
phosphorylation and activation of Mitf after SCF stimulation
[34,36]. Erk-2 has been shown to directly phosphorylate Mitf at
S73 in both melanocytes and melanoma cells. Alternatively, c-KIT
activation can also influence Erk-2 to activate the serine/threonine
kinase p90 Rsk-1 to phosphorylate Mitf at S409. Phosphorylation
of Mitf increases its transcriptional activity and decreases the
protein stability. The biological outcome of this interaction in cell
culture models is to promote melanocyte and melanoma cell
survival. However, genetic analysis of the role of signaling to Mitf
during normal melanocyte development suggests that neither S73
nor S409 are essential during normal melanocyte development in
mice [37,38]. Thus, the signaling from c-KIT to Mitf needs to be
further characterized, especially with respect to the signaling
mechanisms involved. As that both c-KIT and Mitf are essential
factors in the development of melanocyte and melanoma and the
KIT/Mitf Effects on Cell Proliferation
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additional mechanisms and pathways that are controlled by c-KIT
and regulate Mitf are identified. In this study we transfected
HEK293T cells and mouse melanocytes, Melan-A, with c-KIT
and Mitf to elucidate novel signal transduction pathways.
In melanoma, Src family of kinases has the ability to suppress
differentiation and favor proliferation [50]. Src kinases are
responsible for sustained Erk activation, whereby Mitf protein
levels are diminished, resulting in abrogation of differentiation
and pigment production. The c-KIT phosphorylation site Y568
located in the juxtamembrane region of the receptor can act
as a docking site for Src family kinases. The association and
phosphorylation of Src kinase by c-KIT leads to the activation of
Src and phosphorylation of the adaptor protein Shc which in turn
provides association sites for the Grb2/Sos complex and thereby
activating the Ras-Erk pathway. Thus, a substitution mutation of
c-KIT Y568 to phenylalanine would prevent the activation of the
Ras-Erk pathway [14]. In our study, ligand stimulation of wt c-
KIT caused a mobility shift of the Mitf protein. However, when
the c-KIT mutant Y568F was presented with SCF, the Mitf
mobility shift was absent. To further verify the involvement of Src
kinase and Erk in the activation of Mitf, we complemented the
experiment with an inhibitor study. The addition of the Src family
kinase inhibitor (SU6656) and Mek (U0126) inhibitor reversed the
effect of SCF-induced Mitf activation. Although, it is established
that phosphorylation mediated mobility shift of Mitf is generated
by the activation of the Ras-Erk Map kinase pathway, treatment
with a general Mek inhibitor, U0126, did not completely eliminate
the upper band of Mitf. Previous reports [34,36] and our study
(Fig. 2) demonstrate that the upper band is only present in wt Mitf
and that S73A and S409A Mitf mutants exclusively resolve as a
single lower band. Based on these observations one can draw the
conclusion that phosphorylation of both S73 and S409 are
required for the existence of the upper band. However, earlier
studies [36] show that in vitro phosphatase treatment of SCF-
stimulated Mitf only reversed SCF-induced mobility shift of the
protein, leaving the upper band intact. Thus, it seems mobility
shift of Mitf is the consequence of S73 and S409 phosphorylation
and subsequent post translational modification that directly
dictates the occurrence of the upper band. Since, in vivo inhibition
of Mek did not completely abrogate the shift, this suggests the
involvement of additional signaling pathways that might regulate
the modification of Mitf.
The importance of the Ras-Erk pathway in the activation of
Mitf is highlighted in this experiment, in agreement with previous
studies. But, more importantly, we show that the interaction
between Src kinase and c-KIT phosphorylation site Y568 is
required for the activation of Mitf. The Ras-Erk pathway is known
to be critical for cell proliferation and both c-KIT [14] and
Mitf [41] have been shown to affect cell growth through this
cascade. Correspondingly, our cell proliferation study revealed
that in HEK293T cells transfected with Y568F c-KIT and Mitf,
ligand-stimulated proliferation was greatly impaired compared to
wt c-KIT.
One of the functions of Mitf is to indirectly protect the skin
cells from UVB-induced DNA damage by transcribing genes that
controls the production and transfer of melanin to adjacent
keratinocytes. The p38 stress response pathway is triggered by
UVB exposure in human melanocytes. As a result, the level of Mitf
is increased and pigment producing genes are transcribed [45].
This stress pathway is also a signaling component downstream of
c-KIT where the binding of Src kinase to mouse c-KIT Y567
(analogous to human c-KIT Y568) triggers the activation of p38 in
bone marrow derived pro-B cells [16]. These observations
prompted us to investigate whether there is a direct connection
between c-KIT and Mitf through the p38 pathway. Indeed, by
using a p38 inhibitor (SU203580) we show that SCF activation of
Mitf is significantly reduced.
During progression of melanoma, expression of the scaffolding
and adaptor protein Gab2 is often found to be amplified. The
presence of Gab2 aggravates the invasiveness and mestastatic
capabilities of melanoma [51]. Gab2 interacts with receptor
tyrosine kinases including ErbB2 and c-KIT. This adaptor protein
is activated through the binding to c-KIT phosphorylation sites
Y703 and Y936 and potentiates the Ras-Erk and PI3 kinase-Akt
pathways [17–19]. In our study the c-KIT mutant Y703F/Y936F,
despite lacking the Gab2 binding sites, is still able to activate Mitf.
This activity can be explained by the absence of Gab2 expression
from both HEK293T and Melan-A cells. The fact that the
expression of Gab2 either is low or absent in melanocytes [51]
(Fig. 3E) together with the fact that it does not regulate Mitf in our
study, suggest that the role of Gab2 in melanocytes is dispensable.
Although, Gab2 might not be important in melanocytes it has
been shown that Gab2 knock down melanoma cells exhibit
decreased migration and invasion capabilities [51]. Thus, Gab2
and Grb2 signaling in melanoma cells does enhance oncogenic
phenotype [52]; These Gab2-dependent phenotypes are reported
to be mediated via the PI3 kinase-Akt signaling pathway.
The PI3 kinase-Akt survival pathway protects both melanocytes
and melanoma from programmed cell death [42,53]. Interestingly,
inhibition of this signaling pathway increases the production of
melanogenic enzymes through the stimulation of Mitf in mouse
melanoma cells [54]. Clearly, the PI3 kinase-Akt pathway is
involved in the regulation of melanocytic cells and Mitf is a target
of this pathway. However, the participation of c-KIT in this
process has never been studied. PI3 kinase can be activated by
binding of its p85 subunit to c-KIT phosphorylation site Y721.
Here we show that the c-KIT mutant Y721F transiently trans-
fected in both HEK293T and Melan-A cells was unable to activate
Mitf. In addition, inhibitors against PI3 kinase and Akt also
blocked SCF-induced activation of Mitf. Thus, the signal trans-
duction from c-KIT to Mitf seems to be relayed partly through the
Figure 4. C-KIT phosphorylation mutants Y721F, Y568F and Y568F/Y570F are unable to activate Mitf. (A) HEK293T cells were
transfected with wt or mutant forms of c-KIT and Mitf. C-KIT with mutated binding site for the PI3 kinase regulatory subunit p85 (Y721F), did not
result in a Mitf band shift. C-KIT mutants Y568F and Y568F/Y570F, lacking the ability to activated Src, did not activate Mitf upon SCF stimulation.
However, the c-KIT Y703F/Y936F mutant was able to mediate SCF-induced Mitf activation. (B) Mouse melanocytes Melan-A that were treated as
above showed the same Mitf activation pattern. To statistically verify the results, Mitf mobility shift densitometric quantitation was performed on (A)
HEK293T cells and (B) Melan-A cells. Each bar represents the mean 6 SEM for at least three independent experiments. *Denotes significant difference
from positive control p=0.00025. SFC treatment is indicated by gray bars. (C) Immunoprecipitation and subsequent immunoblotting of Gab2 protein
reveal that neither HEK293T cells nor Melan- A melanocytes maintain an endogenous expression. In contrast, Gab2 protein is detected in the positive
control BaF3 cell line.
doi:10.1371/journal.pone.0024064.g004
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PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e24064PI3 kinase-Akt pathway. In our study, blocking of this pathway by
the Y721F mutant of c-KIT leads to decreased proliferation
demonstrating the importance of the PI3-kinase pathway for Mitf-
mediated HEK293T cell proliferation. On the other hand, this
cascade might not be pivotal in melanocytes, since the disruption
of PI3 kinase binding to c-KIT by an Y719F substitution-
mutation of c-KIT (analogous to human c-KIT Y721) in mice did
not produce any pigment defects [11,12].
Our cell proliferation results point out another level of
signaling complexity. As expected, the highest level of cell
proliferation was achieved through the stimulation of wt c-KIT in
the presence of Mitf. Even though SCF stimulation of the
different mutants of c-KIT results in reduced Mitf- dependent
cell growth, the mutants are still quite capable of promoting
proliferation. This phenomenon can be partly explained by the
involvement of other regulators in c-KIT signaling. The c-KIT
phosphorylation sites Y568 and Y570 in the juxtamembrane
domain serve as multifunctional docking sites. Mutation of one or
the other leads to a loss of signalling through multiple pathways.
The phosphorylated Y568 residue does not only act as binding
site for Src family kinases [14], but also for the Csk homologous
kinase [55] which is involved in negative regulation of the Src
family kinase Lyn [56]. In addition, Y568 is the docking site for
the protein tyrosine phosphatase SHP2. SHP2 is known mainly as
a positive regulator of the Ras-Erk pathway. Another protein
tyrosine phosphatase, SHP1, binds to Tyr570 [57]. Thus a
number of positive as well as negative signals emanate from the
juxtamembrane region. To complicate things further, Src family
kinases are known to both positively regulates signalling through
phosphorylation of Shc and subsequent activation of the Ras-Erk
pathway[14] and through phosphorylation of GAB2 [19]. On the
other hand, the ubiquitin E3-ligase Cbl is tyrosine phosphorylat-
ed by Src and involved in ubiquitination and degradation of c-
KIT [58].
Tyrosine 703 and 936 are consensus Grb2 binding sites in that
they have an asparagine residue located two amino acids
downstream of the phosphorylated tyrosine residue. However,
they do not seem to be directly involved in recruitment of Grb2-
Sos to the receptor. Rather, Grb2 acts as an adapter recruiting
either the negative regulator Cbl [59] to the receptor or to the
scaffolding protein GAB2. Thus Y703 and Y936 can mediate both
positive and negative signals by c-KIT.
Figure 5. Inhibitors against Src kinase, Mek, PI3 kinase, Akt and p38 antagonize c-KIT mediated Mitf activation. Thirty minutes prior to
SCF stimulation (A) HEK293T cells and (B) Melan-A cells were treated with Src family kinase inhibitor (SU6656), Mek inhibitor (U0126), PI3 kinase
inhibitor (LY294002) or Akt inhibitor (Akt IV), respectively, all of which prevented c-KIT from activating Mitf. Densitometry analysis was done to
statistically present Mitf mobility shift in (A) HEK293T cells and (B) Melan-A cells. Each bar represents the mean 6 SEM for at least three independent
experiments. *Denotes significant difference from positive control p=0.00025. SFC treatment is indicated by gray bars.
doi:10.1371/journal.pone.0024064.g005
Figure 6. Effects of C-KIT and Mitf on cell proliferation. HEK293T cells transfected with either c-KIT or Mitf did not influence the level of cell
proliferation regardless of SCF stimulation. However, when wt c-KIT or c-KIT Y703F/Y936F and Mitf were introduced, SCF treatment for 48 hours
resulted in an increase in cell numbers. While the c-KIT mutants Y568F and Y721F were able to mediate a proliferative response to SCF stimulation,
the level of increase was significantly (p,0.01) lower compared to wt c-KIT or c-KIT Y703F/Y936F. Each bar represents the average of nine
independent experiments. Error bars signify 95% confidence interval.
doi:10.1371/journal.pone.0024064.g006
KIT/Mitf Effects on Cell Proliferation
PLoS ONE | www.plosone.org 9 August 2011 | Volume 6 | Issue 8 | e24064Y721 is a consensus binding site for the p85 subunit of PI3-
kinase. In cells not expressing GAB2, Y721 is essential for
activation of PI3 kinase by c-KIT [17]. However, in cells
expressing GAB2, activation of PI3-kinase is mediated both by
direct binding of PI3-kinase to Tyr721 as well as indirect binding
to tyrosine phosphorylated GAB2 [19].
To summarize, the signalling income of ligand-stimulation of c-
KIT is very complex, with several pathways initiated by the
receptor feeding into each other and influencing each other. Thus,
when all these components come into play, an apparent loss of
Mitf mobility shift caused by c-KIT mutants Y568F and Y721F
does not necessarily translate into a phenotypic response such as
complete lack of cell proliferation.
In summary, our data show that c-KIT regulates Mitf through
the c-KIT phosphorylation sites Y568, Y570 and Y721 while
Y703 and Y936 are dispensable (Fig. 7). We have identified the
Src, p38, PI3 and Akt kinases to be involved in the regulation of
Mitf. Furthermore, c-KIT mutants Y568F and Y721F lead to
decreased Mitf-dependent cell proliferation compared to wt c-
KIT. Collectively, our results suggest that the activation of Mitf by
c-KIT is more complex than previously indicated. However, the
involvement of the additional pathways we identified need to be
further characterized to reveal their actual role in melanocyte and
melanoma development.
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